Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
LUMINOSITY
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
- NCT03539536 ↗
- Active, not recruiting
- AbbVie
- Deep
We haven't built an HCP commentary report on LUMINOSITY (telisotuzumab vedotin in Non-small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on LUMINOSITY so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 44 | |
| YouTube | 33 | |
| Podcasts | 27 | |
| Bluesky threads | 3 | |
| X videos | 2 |
The trial
ClinicalTrials.gov- Official title
- Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Telisotuzumab vedotin
- Arms
- Telisotuzumab vedotin · Experimental
- Enrollment
- 270
- Primary outcomes
- Overall Response Rate (ORR) (Stage 1 and Stage 2)
- Number of Participants with Adverse Events (Alternate dose cohort)
- Sponsor
- AbbVie
- Start
- Oct 10, 2018
- Primary completion
- Jul 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03539536 · updated Nov 5, 2025
Publications
linked from the registry- Girard N, Goldman J, Lu S, Bar J, Horinouchi H, Daaboul N, Liu C, Cicin I, Katgi N, Zer A, Ciuleanu T, Reinmuth N, Planchard D, Lee SH, Mansfield AS, Moskovitz M, Baijal S, Baik C, Hrom JS, Heist RS, Yazici O, Verma M, Uema D, Patel S, Xia S, Ratajczak C, Camidge DR. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, EGFR Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY Trial. JTO Clin Res Rep. 2026 Mar 16;7(7):100988. doi: 10.1016/j.jtocrr.2026.100988. eCollection 2026 Jul. PubMed 42368479
- Camidge DR, Bar J, Horinouchi H, Goldman J, Moiseenko F, Filippova E, Cicin I, Ciuleanu T, Daaboul N, Liu C, Bradbury P, Moskovitz M, Katgi N, Tomasini P, Zer A, Girard N, Cuppens K, Han JY, Wu SY, Baijal S, Mansfield AS, Kuo CH, Nishino K, Lee SH, Planchard D, Baik C, Li M, Ansell P, Xia S, Bolotin E, Looman J, Ratajczak C, Lu S. Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial. J Clin Oncol. 2024 Sep 1;42(25):3000-3011. doi: 10.1200/JCO.24.00720. Epub 2024 Jun 6. PubMed 38843488